Open AccessFlavopiridol's antiproliferative effects in glioblastoma multiforme
Author(s) -
Gozde Cobanoglu,
İrem Doğan Turaçlı,
Ayla Cihan Ozkan,
Abdullah Ekmekçi
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.172132
Subject(s) - cancer research , cyclin d1 , pten , protein kinase b , western blot , cell growth , apoptosis , kinase , biology , signal transduction , pi3k/akt/mtor pathway , chemistry , microbiology and biotechnology , cell cycle , biochemistry , gene
Glioblastoma multiforme (GBM) is largely refractory to surgical operation, radiotherapy, and chemotherapy in use today. Remaining lifetime accounting for the GBM-affected patients varies between 12 and 16 months generally. The most frequently altered genes in GBM are p53, epidermal growth factor receptor, PTEN, and cyclin-dependent kinase inhibitor 2A. Our aim is to investigate the antiproliferative and apoptotic effects of flavopiridol, a cyclin-dependent kinases and specific phosphokinase inhibitor, on glioblastoma cell lines having different genetic profiles: U87MG, U118MG, and T98G.